Fosfomycin: Use Beyond Urinary Tract and Gastrointestinal Infections
Authors
Discussion
Loading...
Member takes
Implication
Systematic review finds an 81.1% clinical cure rate for fosfomycin in systemic bacterial infections, highlighting its utility against difficult-to-treat pathogens.
Key Points
- To evaluate the clinical effectiveness and safety of fosfomycin for treating and preventing diverse gram-positive and gram-negative bacterial infections outside of uncomplicated urinary and gastrointestinal indications.
- Literature search evaluating 1311 potential records, yielding 62 studies selected for detailed systematic analysis.
- Assessed therapeutic outcomes in 1604 patients with systemic and localized infections across multiple anatomical sites receiving fosfomycin alone or in combination therapy.
- Evaluated infection prevention outcomes in 1212 patients participating in comparative perioperative prophylaxis trials, primarily undergoing colorectal surgery.
- Among 1604 patients receiving fosfomycin for diverse systemic infections, clinical cure occurred in 1302 patients (81.1%) and clinical improvement was observed in 47 patients (2.9%).
- Across perioperative prophylaxis trials comprising 1212 patients, the combination of fosfomycin and metronidazole demonstrated equivalent protective efficacy compared to regimens pairing metronidazole with doxycycline, ampicillin, or cephalothin.
Cite This Study
Falagas et al. (2008) studied this question.